There are currently 208 clinical trials in Worcester, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Massachusetts Medical School, UMass Memorial Medical Center, University of Massachusetts Memorial Medical Center and UMass Memorial Medical Center - University Campus. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251
Recruiting
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: University of Massachusetts Medical School, Worcester, Massachusetts
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
NCT05938725
Recruiting
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2024
Locations: University of Massachusetts Worcester, Worcester, Massachusetts
Conditions: Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: UMass Memorial Medical Center - University Campus, Worcester, Massachusetts
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
VIGOR: Virtual Genome Center for Infant Health
NCT05205356
Recruiting
This study will provide rigorous evaluation of implementing a virtual genome center into community clinical settings without highly specialized resources, thereby offering generalizable insights as to how best to implement genomic medicine at scale and for other age groups. This intervention has great potential to address disparities in genomic medicine among low-income and underrepresented minority (URM) populations and will enhance capacity for providers and health systems to utilize highly sp... Read More
Gender:
ALL
Ages:
Between 0 days and 99 years
Trial Updated:
06/21/2024
Locations: UMass Memorial Hospital, Worcester, Massachusetts
Conditions: Genetics Disease, Genetics/Birth Defects, Genetic Predisposition to Disease
Register for Updates
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: UMass Memorial Medical Center, Worcester, Massachusetts
Conditions: Cholangiocarcinoma
Register for Updates
Botulinum Toxin Therapy in Hidradenitis Suppurativa
NCT05403710
Recruiting
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: University of Massachusetts Chan Medical School, Worcester, Massachusetts
Conditions: Hidradenitis Suppurativa, Hyperhidrosis
Register for Updates
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
NCT05313165
Recruiting
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
05/31/2024
Locations: UMass Chan Medical School, Worcester, Massachusetts
Conditions: Critical Limb Ischemia, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia
Register for Updates
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT04373564
Recruiting
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth. In this study researchers want to find out whether so called gadolinium-based contrast agents (G... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/15/2024
Locations: University of Massachusetts Memorial Medical Center, Worcester, Massachusetts
Conditions: Motor Function, Cognitive Function, Contrast Media
Register for Updates
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
NCT03659448
Recruiting
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: University of Massachusetts, Worcester, Massachusetts
Conditions: Colorectal Neoplasms
Register for Updates
Ultrasound Guided Femoral Nerve Block
NCT02381717
Recruiting
The goal of the study is to evaluate whether pain control achieved by Ultrasound Guided Femoral Nerve Blockade (USFNB) is equal in efficacy to standard pain management practice of parenteral injection of opioid pain medication in patients presenting to the emergency department (ED) with hip fracture.
Gender:
ALL
Ages:
Between 18 years and 101 years
Trial Updated:
04/02/2024
Locations: St. Vincent's Hospital, Worcester, Massachusetts
Conditions: Hip Fracture
Register for Updates
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
NCT04764474
Recruiting
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2024
Locations: University of Massachusetts Medical School, Worcester, Massachusetts
Conditions: Isocitrate Dehydrogenase Gene Mutation
Register for Updates
Comparative Effectiveness of CET vs. SST in SMI (Serious Mental Illness)
NCT04321759
Recruiting
To compare two evidence-based treatments, Cognitive Enhancement Therapy (CET) and Social Skills Training (SST) that have been shown in meta-analyses and in our own research to be effective to improve community functioning. The investigators will test the impact of CET and SST on community functioning, with special attention to their relative effectiveness for patients differing in baseline cognitive skills and age. The research uses a cluster design in which different mental health service cente... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/13/2023
Locations: UMass Medical School, Worcester, Massachusetts
Conditions: Schizophrenia and Related Disorders
Register for Updates